In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF215.00. The company’s shares closed yesterday at $272.80.
Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and AstraZeneca. According to TipRanks, Papadakis has an average return of 6.1% and a 58.15% success rate on recommended stocks.
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $279.76.
See Insiders’ Hot Stocks on TipRanks >>
RHHVF market cap is currently $219.1B and has a P/E ratio of 17.04.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- Roche to hold a virtual neurology analyst and investor event
- Roche, Alnylam report KARDIA-2 study met primary endpoint
- Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
- Roche downgraded to Hold from Buy at Argus
- Biotech Alert: Searches spiking for these stocks today
